Status:
COMPLETED
Affect Treatment for Depression and Anxiety
Lead Sponsor:
University of California, Los Angeles
Collaborating Sponsors:
Southern Methodist University
Conditions:
Depression
Anxiety
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The purpose of this study is to evaluate the efficacy and mediators of change in Positive Affect Treatment, a psychotherapy specifically aimed at enhancing reward sensitivity in individuals with low p...
Detailed Description
Low positive affect in the context of depression or anxiety has been relatively resistant to pharmacological and psychological treatments. Newer treatments that focus upon positivity or reward sensiti...
Eligibility Criteria
Inclusion
- English-speaking
- Low positive affect indexed by less than or equal to 24 on the positive affect subscale of the PANAS (i.e., PANAS-P); and scores of greater than or equal to 11 for depression, greater to or equal to 6 for anxiety, or greater to or equal to 10 for stress on the Depression, Anxiety, and Stress Scale; and scores of greater than or equal to 5 on any Sheehan Disability Scale subscale.
- Willingness to refrain from starting other psychosocial or pharmacological treatments until study completion.
Exclusion
- Patient report of serious medical conditions - such as history of serious, uncontrolled medical illness, or instability (including significant cardio-pulmonary disease, organic brain syndrome, seizure disorder, cerebrovascular disease, thyroid dysfunction, and diabetes)
- Active suicidal ideation
- Lifetime history of bipolar disorder, psychosis, cognitive impairment, or organic brain damage
- Substance abuse in the last 6 months or dependence within last 12 months.
- Greater than 11 cigarettes per week or nicotine equivalent
- History of marijuana, cocaine or stimulant use 5-7 times/week or more before age 15 (e.g., amphetamine, cocaine, methamphetamine)
- Willingness to refrain from marijuana use 1 week before laboratory assessments
- Pregnancy
- Bupropion, dopaminergic or neuroleptic medications use in the past 6 months
- Heterocyclics and SSRIs are permitted if stabilized (3 months) and PRN benzodiazepines and beta-blockers are permitted but discouraged on laboratory assessment visits
- Refusal of video/audio-taping
- Prior participation in previous waves of this study
Key Trial Info
Start Date :
November 22 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 31 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05203861
Start Date
November 22 2021
End Date
May 31 2024
Last Update
April 25 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, Los Angeles
Los Angeles, California, United States, 90095
2
Southern Methodist University
Dallas, Texas, United States, 75205